Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005604 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00005604: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00005604 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005604, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of interleukin-12 plus interleukin-2 in treating patients who have advanced solid tumors. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining the two drugs may kill more cancer cells
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2000-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005604
The ClinicalTrials.gov registry entry for NCT00005604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00005604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005604 about?
NCT00005604 is a clinical study titled "Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors". Phase I trial to study the effectiveness of interleukin-12 plus interleukin-2 in treating patients who have advanced solid tumors. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interleukin-2 may stimulate...
What is the current status of trial NCT00005604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2000-03.
What interventions are being tested in trial NCT00005604?
The interventions under investigation include: laboratory biomarker analysis (OTHER), aldesleukin (BIOLOGICAL), recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005604?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.